A chicory root extract rich in sesquiterpene lactones significantly reduced inflammation in two animal models. In a rat paw edema model, chicory extract at 50 and 100 mg/kg significantly reduced inflammation by 58 and 76%, respectively, 24 h after carrageenan injection. In a mouse collagen induced arthritis model, chicory extract (200 mg/kg) reduced paw edema by 71% while the extract was being administered, and 31% 48 h after extract administration was discontinued. Two possible modes of action were investigated, pro-inflammatory gene expression and nitric oxide production by LPS-elicited macrophages. Chicory root extract down-regulated COX-2, TNF-α, IL1β, and iNOS expression and reduced nitric oxide production in a dose dependant manner. Several compounds were isolated from the chicory extract and tested in vitro to confirm activity. Dihydrolactucopicrin and 8-deoxylactucin showed particularly high nitric oxide inhibitory activity (IC 50 = 13 µM for both). Dihydrolactucopicrin also was shown to down-regulate pro-inflammatory gene expression. These data demonstrate that chicory extracts rich in sesquiterpene lactones have potent anti-inflammatory activity with potential therapeutic use.
Besides its alimentary use, chicory also has a history of medicinal use. Chicory roots have been used as a digestive aid, diuretic, laxative and mild sedative [2] . Hepatoprotective agents have been described in the seeds [3] . Chicory is recognized as a good source of dietary fibers such as inulin and fructooligosaccharides, which have health-promoting properties [2] . Chicory root extracts have been shown to affect cholesterol uptake [4a] and tumor development in mice [4b], prevent immunotoxicity induced by ethanol [4c], have anti-inflammatory proprieties both in vitro and in vivo [4d,4e], and were shown to be non-toxic in rats [4f] . Studies have linked sesquiterpene lactones, the bitter agents in chicory, to some of the anti-inflammatory health benefits. Sesquiterpene lactones are C 15 terpenoid compounds that have a range of biological and pharmaceutical activities [5a,5b] . They have been reported as the active compounds of some wellknown medicinal plants, such as Arnica montana (leopard's bane) [5c] and Tanacetum parthenium (feverfew) [5d] and have been used clinically for migraines [5e] and arthritis [5f] . Studies have shown that sesquiterpene lactones inhibit pro-inflammatory gene expression through inactivation of the transcription factor nuclear factor-kappa B (NF-kB) [5c,5d]. Several pro-inflammatory genes including those coding for cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-α) inducible nitric oxide synthase (iNOS), and interleukin 1, beta (Il1β) contain a binding site in their promoter region for NF-kB [6] and, therefore, their expression can be mediated through the NF-kB pathway.
Inflammation plays an important role in the development of various diseases such as cancer, rheumatoid arthritis, and arteriosclerosis. Inflammatory diseases are currently treated with steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs). Unfortunately, both of these widelyprescribed drug classes have significant negative side effects, reducing their use in certain segments of the population. There is a need to develop new drugs with novel modes of action that do not produce considerable side effects. The use of plant extracts as anti-inflammatory therapeutics is widely reported [7] . With further research, many botanicals may provide safe, efficacious, and cost-effective alternatives to synthetic drugs [7d].
In order to characterize the anti-inflammatory activity of chicory root extract, we investigated its effect on nitric oxide production and pro-inflammatory gene expression in lipopolysaccharide (LPS)-induced macrophages and established activity in acute and chronic rodent inflammation models.
Several sesquiterpene lactones were isolated from chicory root extract that may be responsible for the observed anti-inflammatory activity. Our data suggest that chicory root extract is an effective anti-inflammatory agent that could be developed as a functional food, nutraceutical, or pharmaceutical intended to prevent and treat various inflammatory conditions. The major peaks in a typical LC-MS (electron impact, or EI ionization) total ion current (TIC) chromatogram of chicory root extract ( Figure 1 The putative identification was based on fragmentation patterns, which in the case of EI ionization, is a reproducible and reliable parameter, as well as data from the literature. Thus, peak 4 . The remaining peaks were putatively identified in a similar manner. Additional unequivocal identification will be made by 1 H-, and 13 C-NMR spectroscopy while the demonstrated biological activities are confirmed. Fractions containing smaller peaks and each of the major peaks were isolated using preparative HPLC. Many of the smaller peaks did not have either spectra or fragmentation patterns matching sesquiterpene lactones and were also not active in any of the in vitro assays (Griess or gene expression). Consequently, they were not purified further.
The compound at 14.8 min, ethyl-(p-hydroxyphenyl) acetate, also did not have in vitro anti-inflammatory activity. The 5 major compounds, putatively identified as the sesquiterpene lactones dihydrolactucin, lactucin, 8-deoxylactucin, (epi-) jacquinelin, and dihydrolactucopicrin each had some level of anti-inflammatory activity in vitro and were therefore purified by preparative HPLC and used as standards.
When LPS-induced macrophages were treated with different concentrations of chicory extract for 24 h, nitric oxide production was significantly (p<0.05) reduced in a dose-dependant manner (IC 50 = 21 µg/mL). Chicory extract (21 µg/mL) had a similar inhibitory effect as 13 µM curcumin, a known nitric oxide inhibitor [9] (Table 1) . As mentioned before, fractions containing minor compounds and the larger peak at 14.8 min, putatively identified as (4-OH-phenyl) acetate ethyl-ester, had no nitric oxide inhibitory activity.
The 5 major sesquiterpene lactones present in chicory extract all had some level of nitric oxide inhibition (Table 1) , with 8-deoxylactucin and dihydrolactucopicrin being the most active. Table 1 : IC 50 values of chicory extract, sesquiterpene lactones isolated from chicory, and the known anti-inflammatory compound, curcumin, for nitric oxide production (Griess assay) and pro-inflammatory gene expression (COX-2, iNOS, IL1β and TNF-α) in RAW macrophages elicited with LPS.
There was no evidence of significant cytotoxicity as measured by the MTT assay for chicory extract; curcumin, 8-deoxylactucin, and dihydrolactucopicrin were cytotoxic only at concentrations ten times higher than their IC 50 values (data not shown).
The expression of COX-2, iNOS, TNF-α, and Il1β was significantly decreased in a dose-dependant manner after LPS-induced macrophages were treated with either chicory extract or dihydrolactucopicrin for 6 h (Table 1) . Dihydrolactucopicrin was chosen for gene expression studies because it was highly active in the Griess assay and has never been reported for anti-inflammatory activity, to our knowledge. Although deoxylactucin had similar activity in the Griess assay, it has already been reported to reduce expression of COX-2 [4d]. There was no inhibitory effect on the expression of non-inducible COX-1 for chicory extract (data not shown).
In a rat paw edema model, paw volume of rats treated with vehicle control increased from 1.2 mL baseline to 1.8 mL at 3 h, 1.6 mL at 5 h, and 1.5 mL at 24 h. After 48 h, paw size had returned to baseline. When rats were treated with chicory extract (50 or 100 mg/kg) 1 h after injection of carrageenan in the hind paw, inflammation was reduced for 24 h (Figure 3 ). The 50 mg/kg dose reduced inflammation by 30, 37, and 57% of the control at 3, 5, and 24 h, respectively, with significant differences at 3 and 24 h (p<0.05). The 100 mg/kg dose reduced inflammation by 40, 57, and 76% of the control at 3, 5, and 24 h, respectively with significant results at 3 and 24 h (p<0.05). These effects were very similar to the indomethacin (15 mg/kg) treatment, indicating an antiinflammatory effect. In a collagen induced arthritis model, chicory extract (200 mg/kg) significantly reduced inflammation early in the study, but did not maintain significant activity past day 7 (Figure 4 ). Mice were dosed with chicory extract on days 3-5 and paw size was measured on alternate days beginning on day 5. On day 5, chicory extract reduced inflammation 71% (p=0.002) more than the vehicle control. On day 7, chicory extract was still effective, reducing paw size 31% (p=0.02) more than the control. On day 10, there was a small but statistically insignificant inhibitory effect, 16% (p=0.09) greater than control. In contrast, indomethacin (3 mg/kg) significantly reduced inflammation on days 5-17 (p<0.05). 
Experimental
Extraction procedure: Chicory cv. Sacson roots were provided by Leroux (Lille-Valenciennes, France). Finzelberg GmbH & Co. KG (Andernach, Germany) prepared a sesquiterpene-enriched extract by the following procedure. Dry chicory roots (1 kg) were chipped and extracted in 10 L of 95% ethanol for 24 h at room temperature (24°C). The resulting ethanolic extract was defatted with n-heptane. A secondary extraction of the defatted ethanolic extract with ethyl acetate created an extract rich in sesquiterpene lactones.
Solvents were removed under vacuum, creating 1 g of brown syrup that was lyophilized and stored at 4°C.
LC-MS analysis:
Chicory extract was separated and analyzed with the Waters (Milford, MA) LC-MS Integrity™ system consisting of a solvent delivery system including a W616 pump and W600S controller, W717 plus auto-sampler, W996 PDA detector and Waters TMD Thermabeam™ electron impact (EI) single quadrupole mass detector. Data were collected and analyzed with the Waters Millennium ® v. 3.2 software, linked with the 6 th edition of the Wiley Registry of Mass Spectral Data, containing 229,119 EI spectra of 200,500 compounds. Substances were separated on a Phenomenex ® Luna C-8 reverse phase column, size 150 x 2 mm, particle size 3 µm, pore size 100 Å, equipped with a Phenomenex® SecurityGuard™ pre-column.
The mobile phase consisted of 2 components: Solvent A (0.5% ACS grade acetic acid in double distilled de-ionized water, pH 3-3.5), and Solvent B (100% acetonitrile). The mobile phase flow was adjusted at 0.25 mL/min, and generally a gradient mode was used for all analyses. The gradient points were for time 0.0 min -95% A and 5% B; for time 25.0 min -5% A and 95% B; held isocratic for 2 minutes and from 27.0 min to 30.0 min. -back to initial conditions of 95% A and 5% B. A column equilibration time of 15 min was set between subsequent injections.
Preparatory
HPLC was used to isolate dihydrolactucin, lactucin, 8-deoxylactucin, (epi) jacquinelin, and dihydrolactucopicrin to be used as standards for in vitro assays. Chicory was separated on a Waters preparatory HPLC system consisting of a Waters 600 controller, Waters 486 UV detector set to 254 nm, and Waters 717 autosampler.
A SymmetryShield RP8 7 µm, 19 x 300 mm column was used with a mobile phase consisting of two components: solvent A (0.5% ACS grade acetic acid in double distilled de-ionized water, pH 3-3.5), and solvent B (100% acetonitrile). The mobile phase flow was adjusted to 5 mL/min. Gradient time points were for time 0.0 min, 70% A and 30% B, held isocratic for 10 min; 35.0 min, 0% A and 100% B held isocratic for 5 min, and from 40.0 to 45.0 min changed back to initial conditions of 70% A and 30% B. The column was equilibrated for 15 min between subsequent injections. Identification and purity of compounds was determined using LC-MS as described above.
Cell culture: RAW 264.7 murine monocyte macrophages (ATCC TIB-71) were maintained in Dulbecco's Modified Eagle Medium (D-MEM) supplemented with 10% fetal bovine serum (FBS) and 1% streptomycin and were kept in a humidified 37°C incubator with 5% CO 2 . Cells were subcultured by scraping when plates reached 90% confluency with a 1:5 ratio.
Griess assay for NO production:
The Griess assay was performed to measure indirectly nitric oxide production by LPS-induced macrophages by measuring nitrite [10] .
For the assay, RAW macrophages were plated in a 96-well plate at a minimum density of 5,000 cells/well and grown for 24 h. A stock solution of chicory extract, pure sesquiterpene lactones, or curcumin (Sigma-Aldrich, Inc., St. Louis, MO) was created by completely dissolving dry material in 95% ethanol. Cells were stimulated with 1 µg/mL LPS (Sigma-Aldrich, Inc., St. Louis, MO) with simultaneous addition of chicory extract, pure sesquiterpene lactones, curcumin (10 µM), or vehicle control (0.5% ethanol), maintaining a final concentration of 0.5% ethanol for every treatment. After 24 h, conditioned media (50 µL) was removed and immediately mixed with 100 µL of Griess reagent (10% sulfanilamide, 1% naphthaleneethylenediamine dihydrochloride in 5% H 3 PO 4 ). After incubation for 15 min at room temperature, the samples were read at 550 nm using a microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). Data for each treatment were normalized based on results from an MTT cell proliferation assay.
Quantitative real-time RT-PCR:
Analysis of pro-inflammatory gene expression (COX-2, IL1β, iNOS, and TNF-α) and data analysis were carried out based on previously published methods [11] with one difference. Superscript II Reverse Transcriptase (Invitrogen, Inc., Carlsbad, CA) was used according to manufacturer's instructions instead of Stratascript Reverse Transcriptase (Stratagene, La Jolla, CA) to synthesize cDNAs.
MTT cell proliferation assay:
The MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide, Sigma, St. Louis, MO, USA] tetrazolium dye assay was performed to measure cell viability after 24 h of incubation with treatments. This assay has been widely used as a general measure of in vitro cytotoxicity for plant extracts [12, 13] .
MTT (100 µg/mL) was added to the media of each well and plates were incubated for 3 h. After 3 h, media was removed and dimethylsulfoxide (DMSO, 200 µL) was added to each well to solubilize purple formazan crystals created by mitochondrial dehydrogenase reduction of MTT. After 5 min of additional incubation, absorbance was read at 550 nm on a microplate spectrophotometer (Molecular Devices, Sunnyvale, CA).
Carrageenan induced rat paw edema:
Groups of 5 adult male Wistar rats with body weights from 136 to 170 g were housed, 5 animals per cage, in a room kept at 23-24ºC with 50% humidity and a 12 h light/dark cycle for 1 week prior to initiation of the study. Free access to standard lab chow and tap water was provided throughout. All aspects of this work were performed in accordance with the 1996 Guide for the Care and Use of Laboratory Animals and the protocol was approved by Rutgers University. Before the experiment began, rat paw sizes were recorded by measuring paw volume three times on each animal using a plethysmometer (Ugo Basile, Comerio VA, Italy). The values were averaged to give a baseline paw size value. To start the experiment, animals were given a subcutaneous injection of 1% carrageenan (100 µL per rat; Sigma-Aldrich, Inc., St. Louis, MO) in the area of the back paw to induce an acute inflammatory reaction (paw edema). One h after carrageenan injection, rats were orally gavaged with either chicory extract or vehicle control (4% apricot kernel balm). Paw size was measured at 3, 5, and 24 h after injection. The increase in paw edema at each time point was determined by comparison with paw volume measured pre-injection. Inhibition of edema was calculated by comparison with vehicle control at the same time point.
Collagen induced arthritis:
Groups of 5 male BALB/c mice weighing 25 ± 2 g were housed in Individually Ventilated Cages Racks, in a controlled temperature (23°C-24°C) and humidity (50%) environment with 12 h light/dark cycle for 1 week prior to initiation of the study. Free access to standard lab chow and tap water was provided throughout. All aspects of this work were performed in accordance with the 1996 Guide for the Care and Use of Laboratory Animals and were approved by MDS Pharma Services, Taiwan. Chicory root extract was produced by Phytomedics, Inc. and provided to MDS Pharma Services, Taiwan. For the experiment, a 4 mg/mouse combination of 4 monoclonal antibodies (mAbs) against type II collagen (D8, F10, DI-2G, and A2; IBL Co., Japan) was administered to mice intravenously on day 0 of the study to induce an inflammatory reaction mimicking rheumatoid arthritis. On day 3 of the study, mice were given LPS (25 mg/mouse) intravenously to potentiate the inflammatory effect. One h after LPS administration, mice were dosed orally with chicory (200 mg/kg), indomethacin (3 mg/kg; Sigma, St. Louis, MO), or vehicle control (1% carboxymethylcellulose, CMC; Sigma, St. Louis, MO). Mice were dosed with either chicory or vehicle for two more consecutive days. Volumes of both hind paws were measured using a plethysmometer on days 0, 5, 7, 10, 14, and 17. The increase in paw edema at each time point was determined by comparison with paw volume measured on day 0. Inhibition of edema was calculated by comparison with vehicle control at the same time point. This study was a GLP study (#1038342) performed by MDS Pharma Services (Taiwan).
Statistical analysis:
Data represent means ± SE and were analyzed using either the Student's t-test or ANOVA, where appropriate.
Treatments were considered significantly different if p< 0.001 for gene expression data and p<0.05 for the Griess assay and animal data.
